Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed t...
Gespeichert in:
| Veröffentlicht in: | CNS spectrums Jg. 28; H. 4; S. 416 - 426 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
New York, USA
Cambridge University Press
01.08.2023
|
| Schlagworte: | |
| ISSN: | 1092-8529, 2165-6509 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. |
|---|---|
| AbstractList | Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward. |
| Author | Norman, Trevor R. Carvalho, André F. Berk, Michael Phillips, Arnie Dodd, Seetal Stahl, Stephen M. Eyre, Harris A. |
| Author_xml | – sequence: 1 givenname: Seetal orcidid: 0000-0002-7918-4636 surname: Dodd fullname: Dodd, Seetal email: seetald@barwonhealth.org.au organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia – sequence: 2 givenname: Trevor R. surname: Norman fullname: Norman, Trevor R. organization: Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia – sequence: 3 givenname: Harris A. surname: Eyre fullname: Eyre, Harris A. organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia – sequence: 4 givenname: Stephen M. surname: Stahl fullname: Stahl, Stephen M. organization: 2 Department of Psychiatry, University of California San Diego, San Diego, CA, USA – sequence: 5 givenname: Arnie surname: Phillips fullname: Phillips, Arnie organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia – sequence: 6 givenname: André F. orcidid: 0000-0002-2500-5671 surname: Carvalho fullname: Carvalho, André F. organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia – sequence: 7 givenname: Michael surname: Berk fullname: Berk, Michael organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35811423$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtr3DAQgEVISHaT_oBcgiGXHuJGD1uScwtL0xYWkpK9m7E83ijY1kayW_zvq2W3LWxpYGAO833DPObkuHc9EnLJ6CdGmbp9ZrTgOucF55RSrfURmXEm81TmtDgms2053dbPyDyEV0ozobQ4JWci14xlXMzI96dgW2emyvZJjB5H7zZhMi8WBj_dJZB4_GHxZ-KaxA4h2byA78C41q2nmyRAg0PM0NcJNo01YKYLctJAG_DDPp-T1cPn1eJrunz88m1xv0xNxuSQ1lSbHJUEmVWCQa2wUQqVqUTFtZC0RiikKLSKOzQcNK_yuFnNTMWKTDNxTj7u2m68exsxDGVng8G2hR7dGEoutaZaCi4ien2AvrrR93G4kutMFTqLJ4rU1Z4aqw7rcuNtB34qf98qAmwHGO9C8Nj8QRgtt_8o__lHdNSBY-wAg3X94MG275pib0JXeVuv8e_U_7d-AefKm1o |
| CitedBy_id | crossref_primary_10_1080_00207144_2025_2501964 crossref_primary_10_1007_s11469_025_01489_z crossref_primary_10_1016_j_tips_2023_12_007 crossref_primary_10_1016_j_foodchem_2025_145719 crossref_primary_10_1038_s41380_023_02312_8 crossref_primary_10_3390_ph18071009 crossref_primary_10_1556_2054_2025_00464 crossref_primary_10_3390_pharmaceutics17040411 crossref_primary_10_1177_02698811241286771 crossref_primary_10_1080_14728214_2025_2488786 crossref_primary_10_1055_a_2529_7029 crossref_primary_10_1080_02791072_2024_2399128 crossref_primary_10_3389_fpsyt_2023_1278823 crossref_primary_10_1111_bph_17420 crossref_primary_10_1080_03007995_2024_2396536 crossref_primary_10_1080_14737175_2024_2445016 crossref_primary_10_1111_fcp_70038 crossref_primary_10_1177_02698811231179800 crossref_primary_10_3389_fpsyt_2023_1178529 crossref_primary_10_1007_s40266_025_01221_5 crossref_primary_10_3390_brainsci14080829 crossref_primary_10_37349_en_2025_1006105 crossref_primary_10_1177_20451253251372449 crossref_primary_10_1186_s40337_024_01005_z crossref_primary_10_2147_NDT_S500337 |
| Cites_doi | 10.1007/s12231-011-9152-5 10.1248/bpb.b14-00315 10.1038/mp.2014.24 10.1523/JNEUROSCI.1659-20.2020 10.1111/j.1360-0443.2004.00744.x 10.1098/rsif.2014.0873 10.1038/s41386-020-0694-z 10.1177/0269881108094300 10.1046/j.1528-1157.2002.043s2028.x 10.1097/FBP.0000000000000394 10.1371/journal.pone.0009019 10.1016/S0893-133X(96)00246-1 10.1056/NEJMoa2032994 10.1111/1556-4029.13982 10.1038/s41386-019-0324-9 10.1021/acschemneuro.9b00493 10.3389/fphar.2021.640241 10.7554/eLife.62878 10.1176/appi.ajp.2019.19010035 10.1523/JNEUROSCI.2063-13.2013 10.1001/jamapsychiatry.2020.3285 10.1177/26331055211033847 10.1021/jm000339w 10.1016/j.jchromb.2020.122486 10.1371/journal.pone.0063972 10.1097/00001756-199812010-00024 10.1097/00008877-199811000-00011 10.1016/bs.pbr.2018.08.003 10.1016/j.celrep.2018.05.022 10.1038/sj.npp.1300505 10.1016/j.neuroimage.2020.116980 10.1080/02791072.1998.10399715 10.1007/s00213-017-4771-x 10.1111/acps.12275 10.1080/02791072.2019.1593559 10.1073/pnas.0708862105 10.1001/archgenpsychiatry.2010.116 10.1016/0006-2952(62)90050-3 10.1016/j.biopsych.2012.04.005 10.1016/S0893-133X(98)00089-X 10.1016/j.pharmthera.2018.11.010 10.3389/fpsyt.2021.727117 10.1016/j.neuron.2007.01.008 10.1007/s00221-013-3579-0 10.1021/acschemneuro.8b00186 10.1016/j.neuropharm.2017.12.041 10.1007/s13311-017-0542-y 10.1016/S0893-133X(98)00108-0 10.3389/fpsyt.2017.00240 10.1038/s41398-021-01603-4 10.1016/j.euroneuro.2013.12.006 10.1007/s12231-008-9033-8 10.1080/03602532.2016.1278228 10.1016/j.euroneuro.2016.05.001 10.1093/ijnp/pyx047 10.1080/10550887.2019.1673655 10.1073/pnas.1119598109 10.1016/S0031-6865(97)00014-9 10.1016/j.psychres.2020.112749 10.1016/S0731-7085(02)00278-9 10.1111/j.1476-5381.2011.01516.x 10.1002/hlca.19590420518 10.1177/0269881114565144 10.1016/bs.pbr.2018.09.013 10.1016/j.jchromb.2011.07.003 10.1038/nrn2884 10.1016/j.brainresbull.2016.04.016 10.1016/j.neuropharm.2019.107933 10.1080/1355621021000005937 10.1007/s00213-014-3557-7 10.1177/0269881110382466 10.1016/j.neuropharm.2018.05.012 10.1007/s40262-017-0540-6 10.1007/BF02160424 10.1177/0269881116675513 10.1038/s41598-017-13282-7 10.1177/0269881119895520 10.1016/j.biopsych.2014.04.010 10.1177/0269881116675512 10.1124/dmd.109.031138 10.1177/096032718200100408 10.3109/00952990.2016.1170135 10.1038/npp.2011.228 10.1080/02791072.1989.10472149 10.1016/S0378-4347(98)00067-X 10.1038/s41591-022-01744-z 10.1016/0028-3908(90)90001-8 10.1007/s00213-022-06123-7 |
| ContentType | Journal Article |
| Copyright | The Author(s), 2022. Published by Cambridge University Press The Author(s), 2022. Published by Cambridge University Press. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s), 2022. Published by Cambridge University Press – notice: The Author(s), 2022. Published by Cambridge University Press. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | IKXGN AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PSYQQ Q9U 7X8 |
| DOI | 10.1017/S1092852922000888 |
| DatabaseName | Cambridge University Press Wholly Gold Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Psychology Database (ProQuest) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: IKXGN name: Cambridge University Press Wholly Gold Open Access Journals url: http://journals.cambridge.org/action/login sourceTypes: Publisher – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2165-6509 |
| EndPage | 426 |
| ExternalDocumentID | 35811423 10_1017_S1092852922000888 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E. .GJ 09C 09E 0E1 0R~ 123 29B 36B 53G 5VS 6PF 7X7 8FI 8FJ AAAZR AABES AABWE AACJH AAEED AAGFV AAKTX AARAB AASVR AAUKB AAWTL ABBXD ABBZL ABGDZ ABJNI ABKKG ABMYL ABQTM ABROB ABUWG ABWCF ABXAU ABZCX ABZUI ACBMC ACCHT ACETC ACGFO ACGFS ACIMK ACQFJ ACREK ACUIJ ACUYZ ACWGA ACYZP ACZBM ACZUX ADAZD ADDNB ADFEC ADGEJ ADKIL ADOCW ADOVH ADOVT ADVJH AEBAK AEBPU AEHGV AENCP AENEX AENGE AEPLO AEYHU AEYYC AFFUJ AFKQG AFKRA AFLOS AFLVW AFUTZ AGABE AGJUD AGLWM AGOOT AHIPN AHLTW AHQXX AHRGI AIGNW AIHIV AIOIP AISIE AJCYY AJPFC AJQAS AKZCZ ALMA_UNASSIGNED_HOLDINGS ANPSP AQJOH ARABE ARZZG ATUCA AUXHV AYIQA AZGZS AZQEC BBLKV BCGOX BENPR BESQT BGHMG BJBOZ BLZWO BMAJL BQFHP BRIRG C0O C1A C45 CBIIA CCPQU CCQAD CCUQV CFAFE CFBFF CGQII CHEAL CJCSC DC4 DOHLZ DWQXO E3Z EBS EGQIC EJD EMB EMOBN F5P FYUFA GNUQQ HG- HMCUK HZ~ I.6 I.7 I.9 IH6 IKXGN IOEEP IOO IS6 I~P JHPGK JQKCU JVRFK KAFGG KCGVB KFECR LHUNA LW7 M-V M2M NIKVX NZEOI O9- OHT OK1 OVD P2P PSYQQ RCA ROL RR0 S6- S6U SAAAG SJN SV3 SY4 T9M TEORI TR2 UKHRP UT1 UU6 WFFJZ WXY ZDLDU ZJOSE ZMEZD ZYDXJ AATMM AAXMD AAYXX ABVKB ABVZP ABXHF ACDLN ACRPL ADNMO AEMFK AEMTJ AFFHD AFZFC AGQPQ AKMAY CITATION IPYYG PHGZM PHGZT CGR CUY CVF ECM EIF NPM PUEGO 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8 |
| ID | FETCH-LOGICAL-c416t-d08c5e76a64b31ad7ef77e7cb3b28360dea963987092f2a82b5165d1cb194813 |
| IEDL.DBID | IKXGN |
| ISICitedReferencesCount | 36 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000844412000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1092-8529 |
| IngestDate | Fri Sep 05 12:46:38 EDT 2025 Tue Oct 07 07:24:14 EDT 2025 Thu Sep 11 02:52:50 EDT 2025 Tue Nov 18 22:20:55 EST 2025 Sat Nov 29 01:31:37 EST 2025 Wed Mar 13 05:53:53 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | treatment anxiety neuroscience safety Psilocybin psychiatry depression adverse events posttraumatic stress disorder |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c416t-d08c5e76a64b31ad7ef77e7cb3b28360dea963987092f2a82b5165d1cb194813 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-2500-5671 0000-0002-7918-4636 |
| OpenAccessLink | https://www.cambridge.org/core/product/identifier/S1092852922000888/type/journal_article |
| PMID | 35811423 |
| PQID | 2847984529 |
| PQPubID | 5528237 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2688086323 proquest_journals_2847984529 pubmed_primary_35811423 crossref_primary_10_1017_S1092852922000888 crossref_citationtrail_10_1017_S1092852922000888 cambridge_journals_10_1017_S1092852922000888 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-01 |
| PublicationDateYYYYMMDD | 2023-08-01 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York, USA |
| PublicationPlace_xml | – name: New York, USA – name: United States – name: New York |
| PublicationTitle | CNS spectrums |
| PublicationTitleAlternate | CNS Spectr |
| PublicationYear | 2023 |
| Publisher | Cambridge University Press |
| Publisher_xml | – name: Cambridge University Press |
| References | 2010; 11 2015; 78 2017; 7 2018; 242 2017; 8 2011; 879 2012; 165 2015; 38 2019; 51 2004; 29 2020; 284 2017; 49 2000; 43 1958; 14 2017; 43 2016; 30 2014; 24 2008; 105 2020; 167 2013; 8 2014; 130 2022; 28 2021; 1164 2012; 72 2018; 9 2021; 78 1982; 1 2019; 64 2002; 43 2011; 65 1975; 1 1997; 16 2020; 177 2011; 68 2020; 45 2008; 22 2011; 25 2008; 62 2010; 5 2021; 41 2014; 11 2020; 218 2018; 37 2019; 197 2018; 142 2018; 29 2017; 20 1959; 42 2010; 38 1989; 1 1989; 21 2002; 30 2002; 7 2013; 228 1999; 20 2021; 384 2020; 34 2016; 126 1962; 11 2012; 37 2014; 231 2018; 23 2007; 53 2022; 239 2012; 109 2004; 99 2021; 16 2021; 10 1997; 72 2021; 12 2021; 11 2015; 29 2013; 33 2017; 14 1998; 709 2019; 44 1990; 29 2015; 20 2017; 56 2018; 235 1998; 30 2016; 26 1998; 9 Eivindvik (S1092852922000888_r17) 1989; 1 S1092852922000888_r48 S1092852922000888_r49 S1092852922000888_r46 S1092852922000888_r47 S1092852922000888_r44 S1092852922000888_r88 S1092852922000888_r45 S1092852922000888_r89 S1092852922000888_r42 S1092852922000888_r86 S1092852922000888_r87 S1092852922000888_r43 S1092852922000888_r40 S1092852922000888_r84 S1092852922000888_r41 S1092852922000888_r85 S1092852922000888_r82 S1092852922000888_r83 S1092852922000888_r80 S1092852922000888_r81 Aghajanian (S1092852922000888_r29) 1975; 1 S1092852922000888_r19 S1092852922000888_r18 S1092852922000888_r59 S1092852922000888_r15 S1092852922000888_r16 S1092852922000888_r57 S1092852922000888_r13 S1092852922000888_r58 S1092852922000888_r14 S1092852922000888_r11 S1092852922000888_r55 S1092852922000888_r56 S1092852922000888_r12 S1092852922000888_r53 S1092852922000888_r54 S1092852922000888_r10 S1092852922000888_r51 S1092852922000888_r52 S1092852922000888_r93 S1092852922000888_r50 S1092852922000888_r94 S1092852922000888_r91 S1092852922000888_r90 S1092852922000888_r28 S1092852922000888_r26 S1092852922000888_r27 S1092852922000888_r68 S1092852922000888_r24 S1092852922000888_r69 S1092852922000888_r25 S1092852922000888_r22 S1092852922000888_r66 S1092852922000888_r23 S1092852922000888_r67 S1092852922000888_r64 S1092852922000888_r20 S1092852922000888_r65 S1092852922000888_r21 S1092852922000888_r62 S1092852922000888_r63 S1092852922000888_r60 S1092852922000888_r61 S1092852922000888_r3 S1092852922000888_r2 S1092852922000888_r5 S1092852922000888_r4 S1092852922000888_r7 S1092852922000888_r6 S1092852922000888_r9 S1092852922000888_r8 S1092852922000888_r39 S1092852922000888_r1 S1092852922000888_r37 S1092852922000888_r38 S1092852922000888_r35 S1092852922000888_r79 S1092852922000888_r36 S1092852922000888_r77 Dimsdale (S1092852922000888_r92) 2021 S1092852922000888_r33 S1092852922000888_r34 S1092852922000888_r78 S1092852922000888_r31 S1092852922000888_r75 S1092852922000888_r76 S1092852922000888_r32 S1092852922000888_r73 S1092852922000888_r30 S1092852922000888_r74 S1092852922000888_r71 S1092852922000888_r72 S1092852922000888_r70 |
| References_xml | – volume: 78 start-page: 481 issue: 5 year: 2021 end-page: 489 article-title: Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial publication-title: JAMA Psychiatry. – volume: 72 start-page: 175 issue: 3 year: 1997 end-page: 184 article-title: Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man publication-title: Pharm Acta Helv. – volume: 30 start-page: 331 issue: 2 year: 2002 end-page: 339 article-title: Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man publication-title: J Pharm Biomed Anal. – volume: 42 start-page: 1557 issue: 5 year: 1959 end-page: 1572 article-title: Psilocybin und psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen publication-title: Helvetica Chimica Acta. – volume: 26 start-page: 1327 issue: 8 year: 2016 end-page: 1337 article-title: Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens publication-title: Eur Neuropsychopharmacol. – volume: 33 start-page: 15171 issue: 38 year: 2013 end-page: 15183 article-title: Broadband cortical desynchronization underlies the human psychedelic state publication-title: J Neurosci. – volume: 20 start-page: 311 issue: 3 year: 2015 end-page: 319 article-title: Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis publication-title: Mol Psychiatry – volume: 43 start-page: 4701 issue: 24 year: 2000 end-page: 4710 article-title: Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines publication-title: J Med Chem. – volume: 29 start-page: 2081 issue: 11 year: 2004 end-page: 2087 article-title: Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients publication-title: Neuropsychopharmacology. – volume: 29 start-page: 530 issue: 6 year: 2018 end-page: 536 article-title: Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats publication-title: Behav Pharmacol. – volume: 1 start-page: 417 issue: 4 year: 1982 end-page: 424 article-title: The problem of psilocybin mushroom abuse publication-title: Hum Toxicol. – volume: 29 start-page: 289 issue: 3 year: 2015 end-page: 299 article-title: Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study publication-title: J Psychopharmacol. – volume: 177 start-page: 391 issue: 5 year: 2020 end-page: 410 article-title: Psychedelics and psychedelic-assisted psychotherapy publication-title: Am J Psychiatry. – volume: 43 start-page: 28 issue: Suppl 2 year: 2002 end-page: 31 article-title: Psychostimulants and epilepsy publication-title: Epilepsia. – volume: 1164 start-page: 122486 year: 2021 article-title: Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 7 start-page: 357 issue: 4 year: 2002 end-page: 364 article-title: The pharmacology of psilocybin publication-title: Addict Biol. – volume: 72 start-page: 898 issue: 11 year: 2012 end-page: 906 article-title: Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors publication-title: Biol Psychiatry. – volume: 9 start-page: 561 issue: 7 year: 1998 end-page: 566 article-title: Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans publication-title: Behav Pharmacol. – volume: 30 start-page: 419 issue: 4 year: 1998 end-page: 426 article-title: Dr. Leary’s Concord Prison Experiment: a 34-year follow-up study publication-title: J Psychoactive Drugs. – volume: 49 start-page: 84 issue: 1 year: 2017 end-page: 91 article-title: Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance publication-title: Drug Metab Rev. – volume: 231 start-page: 4135 issue: 21 year: 2014 end-page: 4144 article-title: Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes publication-title: Psychopharmacology – volume: 11 start-page: 642 issue: 9 year: 2010 end-page: 651 article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders publication-title: Nat Rev Neurosci. – volume: 228 start-page: 481 issue: 4 year: 2013 end-page: 491 article-title: Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning publication-title: Exp Brain Res. – volume: 25 start-page: 1434 issue: 11 year: 2011 end-page: 1452 article-title: Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies publication-title: J Psychopharmacol. – volume: 142 start-page: 143 year: 2018 end-page: 166 article-title: The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act publication-title: Neuropharmacology. – volume: 14 start-page: 397 issue: 11 year: 1958 end-page: 399 article-title: Elucidation of the structure and the synthesis of psilocybin publication-title: Experientia. – volume: 30 start-page: 1181 issue: 12 year: 2016 end-page: 1197 article-title: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial publication-title: J Psychopharmacol. – volume: 45 start-page: 1316 issue: 8 year: 2020 end-page: 1322 article-title: Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse publication-title: Neuropsychopharmacology. – volume: 78 start-page: 572 issue: 8 year: 2015 end-page: 581 article-title: Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers publication-title: Biol Psychiatry. – volume: 165 start-page: 1046 issue: 4b year: 2012 end-page: 1057 article-title: Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects publication-title: Br J Pharmacol – volume: 105 start-page: 1079 issue: 3 year: 2008 end-page: 1084 article-title: Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo publication-title: Proc Natl Acad Sci U S A – volume: 22 start-page: 621 issue: 6 year: 2008 end-page: 632 article-title: Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. publication-title: J Psychopharmacol. – volume: 34 start-page: 167 issue: 2 year: 2020 end-page: 180 article-title: Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression publication-title: J Psychopharmacol. – volume: 24 start-page: 342 issue: 3 year: 2014 end-page: 356 article-title: Psilocybin - summary of knowledge and new perspectives publication-title: Eur Neuropsychopharmacol. – volume: 28 start-page: 844 issue: 4 year: 2022 end-page: 851 article-title: Increased global integration in the brain after psilocybin therapy for depression publication-title: Nat Med. – volume: 284 start-page: 112749 year: 2020 article-title: The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis publication-title: Psychiatry Res. – volume: 14 start-page: 734 issue: 3 year: 2017 end-page: 740 article-title: Potential therapeutic effects of psilocybin publication-title: Neurotherapeutics. – volume: 16 start-page: 357 issue: 5 year: 1997 end-page: 372 article-title: Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis publication-title: Neuropsychopharmacology. – volume: 1 start-page: 295 issue: 5 year: 1989 end-page: 302 article-title: Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon publication-title: Acta Pharm Nord. – volume: 11 start-page: 20140873 issue: 101 year: 2014 article-title: Homological scaffolds of brain functional networks publication-title: J R Soc Interface. – volume: 197 start-page: 83 year: 2019 end-page: 102 article-title: Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function publication-title: Pharmacol Ther. – volume: 11 start-page: 506 issue: 1 year: 2021 article-title: Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity publication-title: Transl Psychiatry. – volume: 30 start-page: 1165 issue: 12 year: 2016 end-page: 1180 article-title: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial publication-title: J Psychopharmacol. – volume: 65 start-page: 121 issue: 2 year: 2011 end-page: 128 article-title: A prehistoric mural in spain depicting neurotropic psilocybe mushrooms? publication-title: Econ Bot – volume: 38 start-page: 386 issue: 3 year: 2010 end-page: 395 article-title: Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases publication-title: Drug Metab Dispos. – volume: 11 start-page: 261 year: 1962 end-page: 269 article-title: The fate of psilocin in the rat publication-title: Biochem Pharmacol. – volume: 53 start-page: 439 issue: 3 year: 2007 end-page: 452 article-title: Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior publication-title: Neuron. – volume: 12 start-page: 640241 year: 2021 article-title: Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property publication-title: Front Pharmacol. – volume: 1 start-page: 619 issue: 6 year: 1975 end-page: 629 article-title: Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors publication-title: Psychopharmacol Commun. – volume: 43 start-page: 55 issue: 1 year: 2017 end-page: 60 article-title: Long-term follow-up of psilocybin-facilitated smoking cessation publication-title: Am J Drug Alcohol Abuse. – volume: 20 start-page: 747 issue: 9 year: 2017 end-page: 757 article-title: Effect of psilocybin on empathy and moral decision-making publication-title: Int J Neuropsychopharmacol. – volume: 44 start-page: 1328 issue: 7 year: 2019 end-page: 1334 article-title: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels publication-title: Neuropsychopharmacology. – volume: 242 start-page: 25 year: 2018 end-page: 67 article-title: The renaissance in psychedelic research: What do preclinical models have to offer publication-title: Prog Brain Res. – volume: 51 start-page: 174 issue: 2 year: 2019 end-page: 188 article-title: Psychedelic-assisted group therapy: a systematic review publication-title: J Psychoactive Drugs. – volume: 218 start-page: 116980 year: 2020 article-title: Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention publication-title: Neuroimage. – volume: 99 start-page: 686 issue: 6 year: 2004 end-page: 696 article-title: Comparison of acute lethal toxicity of commonly abused psychoactive substances publication-title: Addiction. – volume: 384 start-page: 1402 issue: 15 year: 2021 end-page: 1411 article-title: Trial of psilocybin versus escitalopram for depression publication-title: N Engl J Med – volume: 142 start-page: 263 year: 2018 end-page: 269 article-title: Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression publication-title: Neuropharmacology. – volume: 10 start-page: e62878 year: 2021 article-title: Self-blinding citizen science to explore psychedelic microdosing publication-title: Elife – volume: 38 start-page: 134 issue: 1 year: 2015 end-page: 138 article-title: Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats publication-title: Biol Pharm Bull. – volume: 62 start-page: 404 issue: 3 year: 2008 end-page: 412 article-title: Hallucinogenic mushrooms in Mexico: an overview publication-title: Econ Bot. – volume: 126 start-page: 74 issue: Pt 1 year: 2016 end-page: 88 article-title: Neuropharmacology of N,N-dimethyltryptamine publication-title: Brain Res Bull. – volume: 64 start-page: 1266 issue: 4 year: 2019 end-page: 1270 article-title: Unpredictable behavior under the influence of “magic mushrooms”: a case report and review of the literature publication-title: J Forensic Sci. – volume: 8 start-page: e63972 issue: 8 year: 2013 article-title: Psychedelics and mental health: a population study publication-title: PLoS One. – volume: 242 start-page: 1 year: 2018 end-page: 23 article-title: An introduction to psychedelic neuroscience publication-title: Prog Brain Res. – volume: 9 start-page: 2438 issue: 10 year: 2018 end-page: 2447 article-title: DARK classics in chemical neuroscience: psilocybin publication-title: ACS Chem Neurosci. – volume: 879 start-page: 2669 issue: 25 year: 2011 end-page: 2672 article-title: Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis publication-title: J Chromatogr B Analyt Technol Biomed Life Sci. – volume: 12 start-page: 727117 year: 2021 article-title: Psychedelics and other psychoplastogens for treating mental illness publication-title: Front Psychiatry. – volume: 709 start-page: 255 issue: 2 year: 1998 end-page: 263 article-title: Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid–liquid extraction with automated on-line solid-phase extraction publication-title: J Chromatogr B Biomed Sci Appl. – volume: 56 start-page: 1543 issue: 12 year: 2017 end-page: 1554 article-title: Pharmacokinetics of escalating doses of oral psilocybin in healthy adults publication-title: Clin Pharmacokinet. – volume: 235 start-page: 399 issue: 2 year: 2018 end-page: 408 article-title: Psilocybin with psychological support for treatment-resistant depression: six-month follow-up publication-title: Psychopharmacology (Berl). – volume: 167 start-page: 107933 year: 2020 article-title: Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species publication-title: Neuropharmacology. – volume: 5 start-page: e9019 issue: 2 year: 2010 article-title: Psychedelics and the human receptorome publication-title: PLoS One – volume: 239 start-page: 1989 year: 2022 end-page: 2010 article-title: Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials publication-title: Psychopharmacology (Berl) – volume: 41 start-page: 891 issue: 5 year: 2021 end-page: 900 article-title: Hallucinogens in mental health: preclinical and clinical studies on LSD, Psilocybin, MDMA, and Ketamine publication-title: J Neurosci. – volume: 21 start-page: 123 issue: 1 year: 1989 end-page: 128 article-title: Shamans, sacraments, and psychiatrists publication-title: J Psychoactive Drugs. – volume: 20 start-page: 424 issue: 5 year: 1999 end-page: 433 article-title: 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [11C]raclopride publication-title: Neuropsychopharmacology. – volume: 9 start-page: 3897 issue: 17 year: 1998 end-page: 3902 article-title: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action publication-title: Neuroreport. – volume: 7 start-page: 13187 issue: 1 year: 2017 article-title: Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms publication-title: Sci Rep. – volume: 20 start-page: 565 issue: 6 year: 1999 end-page: 581 article-title: Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG publication-title: Neuropsychopharmacology. – volume: 37 start-page: 268 issue: 3–4 year: 2018 end-page: 278 article-title: Hallucinogenpersisting perception disorder: a literature review and three case reports publication-title: J Addict Dis. – volume: 23 start-page: 3170 issue: 11 year: 2018 end-page: 3182 article-title: Psychedelics promote structural and functional neural plasticity publication-title: Cell Rep. – volume: 109 start-page: 2138 issue: 6 year: 2012 end-page: 2143 article-title: Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin publication-title: Proc Natl Acad Sci U S A. – volume: 29 start-page: 193 issue: 3 year: 1990 end-page: 198 article-title: Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes publication-title: Neuropharmacology. – volume: 130 start-page: 181 issue: 3 year: 2014 end-page: 192 article-title: Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis publication-title: Acta Psychiatr Scand – volume: 68 start-page: 71 issue: 1 year: 2011 end-page: 78 article-title: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer publication-title: Arch Gen Psychiatry. – volume: 37 start-page: 630 issue: 3 year: 2012 end-page: 640 article-title: Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers publication-title: Neuropsychopharmacology. – volume: 16 start-page: 26331055211033847 year: 2021 article-title: Engineering safer psychedelics for treating addiction publication-title: Neurosci Insights. – volume: 8 start-page: 240 year: 2017 article-title: The “endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review publication-title: Front Psychiatry. – ident: S1092852922000888_r2 doi: 10.1007/s12231-011-9152-5 – ident: S1092852922000888_r41 doi: 10.1248/bpb.b14-00315 – ident: S1092852922000888_r56 doi: 10.1038/mp.2014.24 – ident: S1092852922000888_r31 doi: 10.1523/JNEUROSCI.1659-20.2020 – ident: S1092852922000888_r61 doi: 10.1111/j.1360-0443.2004.00744.x – ident: S1092852922000888_r53 doi: 10.1098/rsif.2014.0873 – ident: S1092852922000888_r75 doi: 10.1038/s41386-020-0694-z – ident: S1092852922000888_r90 doi: 10.1177/0269881108094300 – ident: S1092852922000888_r65 doi: 10.1046/j.1528-1157.2002.043s2028.x – ident: S1092852922000888_r74 doi: 10.1097/FBP.0000000000000394 – ident: S1092852922000888_r27 doi: 10.1371/journal.pone.0009019 – ident: S1092852922000888_r47 doi: 10.1016/S0893-133X(96)00246-1 – ident: S1092852922000888_r82 doi: 10.1056/NEJMoa2032994 – ident: S1092852922000888_r70 doi: 10.1111/1556-4029.13982 – ident: S1092852922000888_r23 doi: 10.1038/s41386-019-0324-9 – ident: S1092852922000888_r72 doi: 10.1021/acschemneuro.9b00493 – ident: S1092852922000888_r73 doi: 10.3389/fphar.2021.640241 – volume: 1 start-page: 295 year: 1989 ident: S1092852922000888_r17 article-title: Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon publication-title: Acta Pharm Nord. – ident: S1092852922000888_r88 doi: 10.7554/eLife.62878 – ident: S1092852922000888_r5 doi: 10.1176/appi.ajp.2019.19010035 – ident: S1092852922000888_r49 doi: 10.1523/JNEUROSCI.2063-13.2013 – ident: S1092852922000888_r79 doi: 10.1001/jamapsychiatry.2020.3285 – ident: S1092852922000888_r38 doi: 10.1177/26331055211033847 – ident: S1092852922000888_r26 doi: 10.1021/jm000339w – ident: S1092852922000888_r16 doi: 10.1016/j.jchromb.2020.122486 – ident: S1092852922000888_r68 doi: 10.1371/journal.pone.0063972 – ident: S1092852922000888_r32 doi: 10.1097/00001756-199812010-00024 – ident: S1092852922000888_r63 doi: 10.1097/00008877-199811000-00011 – ident: S1092852922000888_r71 doi: 10.1016/bs.pbr.2018.08.003 – ident: S1092852922000888_r37 doi: 10.1016/j.celrep.2018.05.022 – ident: S1092852922000888_r39 doi: 10.1038/sj.npp.1300505 – ident: S1092852922000888_r54 doi: 10.1016/j.neuroimage.2020.116980 – ident: S1092852922000888_r85 doi: 10.1080/02791072.1998.10399715 – ident: S1092852922000888_r83 doi: 10.1007/s00213-017-4771-x – volume: 1 start-page: 619 year: 1975 ident: S1092852922000888_r29 article-title: Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors publication-title: Psychopharmacol Commun. – ident: S1092852922000888_r80 doi: 10.1111/acps.12275 – ident: S1092852922000888_r6 doi: 10.1080/02791072.2019.1593559 – ident: S1092852922000888_r7 – ident: S1092852922000888_r44 doi: 10.1073/pnas.0708862105 – ident: S1092852922000888_r76 doi: 10.1001/archgenpsychiatry.2010.116 – ident: S1092852922000888_r20 doi: 10.1016/0006-2952(62)90050-3 – ident: S1092852922000888_r33 doi: 10.1016/j.biopsych.2012.04.005 – ident: S1092852922000888_r48 doi: 10.1016/S0893-133X(98)00089-X – ident: S1092852922000888_r46 doi: 10.1016/j.pharmthera.2018.11.010 – ident: S1092852922000888_r94 doi: 10.3389/fpsyt.2021.727117 – ident: S1092852922000888_r43 doi: 10.1016/j.neuron.2007.01.008 – ident: S1092852922000888_r45 doi: 10.1007/s00221-013-3579-0 – ident: S1092852922000888_r62 – volume-title: Dark Persuasion: A History of Brainwashing from Pavlov to Social Media year: 2021 ident: S1092852922000888_r92 – ident: S1092852922000888_r1 doi: 10.1021/acschemneuro.8b00186 – ident: S1092852922000888_r66 – ident: S1092852922000888_r57 doi: 10.1016/j.neuropharm.2017.12.041 – ident: S1092852922000888_r4 doi: 10.1007/s13311-017-0542-y – ident: S1092852922000888_r42 doi: 10.1016/S0893-133X(98)00108-0 – ident: S1092852922000888_r69 doi: 10.3389/fpsyt.2017.00240 – ident: S1092852922000888_r50 doi: 10.1038/s41398-021-01603-4 – ident: S1092852922000888_r35 doi: 10.1016/j.euroneuro.2013.12.006 – ident: S1092852922000888_r3 doi: 10.1007/s12231-008-9033-8 – ident: S1092852922000888_r19 doi: 10.1080/03602532.2016.1278228 – ident: S1092852922000888_r25 doi: 10.1016/j.euroneuro.2016.05.001 – ident: S1092852922000888_r89 doi: 10.1093/ijnp/pyx047 – ident: S1092852922000888_r67 doi: 10.1080/10550887.2019.1673655 – ident: S1092852922000888_r52 doi: 10.1073/pnas.1119598109 – ident: S1092852922000888_r12 doi: 10.1016/S0031-6865(97)00014-9 – ident: S1092852922000888_r81 doi: 10.1016/j.psychres.2020.112749 – ident: S1092852922000888_r14 doi: 10.1016/S0731-7085(02)00278-9 – ident: S1092852922000888_r40 doi: 10.1111/j.1476-5381.2011.01516.x – ident: S1092852922000888_r10 doi: 10.1002/hlca.19590420518 – ident: S1092852922000888_r87 doi: 10.1177/0269881114565144 – ident: S1092852922000888_r51 doi: 10.1016/bs.pbr.2018.09.013 – ident: S1092852922000888_r21 doi: 10.1016/j.jchromb.2011.07.003 – ident: S1092852922000888_r30 doi: 10.1038/nrn2884 – ident: S1092852922000888_r9 doi: 10.1016/j.brainresbull.2016.04.016 – ident: S1092852922000888_r36 doi: 10.1016/j.neuropharm.2019.107933 – ident: S1092852922000888_r18 doi: 10.1080/1355621021000005937 – ident: S1092852922000888_r28 doi: 10.1007/s00213-014-3557-7 – ident: S1092852922000888_r91 doi: 10.1177/0269881110382466 – ident: S1092852922000888_r8 doi: 10.1016/j.neuropharm.2018.05.012 – ident: S1092852922000888_r15 doi: 10.1007/s40262-017-0540-6 – ident: S1092852922000888_r11 doi: 10.1007/BF02160424 – ident: S1092852922000888_r78 doi: 10.1177/0269881116675513 – ident: S1092852922000888_r55 doi: 10.1038/s41598-017-13282-7 – ident: S1092852922000888_r58 doi: 10.1177/0269881119895520 – ident: S1092852922000888_r59 doi: 10.1016/j.biopsych.2014.04.010 – ident: S1092852922000888_r77 doi: 10.1177/0269881116675512 – ident: S1092852922000888_r22 doi: 10.1124/dmd.109.031138 – ident: S1092852922000888_r64 doi: 10.1177/096032718200100408 – ident: S1092852922000888_r86 doi: 10.3109/00952990.2016.1170135 – ident: S1092852922000888_r34 doi: 10.1038/npp.2011.228 – ident: S1092852922000888_r84 doi: 10.1080/02791072.1989.10472149 – ident: S1092852922000888_r13 doi: 10.1016/S0378-4347(98)00067-X – ident: S1092852922000888_r60 doi: 10.1038/s41591-022-01744-z – ident: S1092852922000888_r24 doi: 10.1016/0028-3908(90)90001-8 – ident: S1092852922000888_r93 doi: 10.1007/s00213-022-06123-7 |
| SSID | ssj0043783 |
| Score | 2.5115426 |
| SecondaryResourceType | review_article |
| Snippet | Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the... Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the... Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybin has four metabolites including the pharmacologically... |
| SourceID | proquest pubmed crossref cambridge |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 416 |
| SubjectTerms | Drug dosages Hallucinogens - adverse effects Hallucinogens - pharmacology Hallucinogens - therapeutic use Humans Mental Disorders - drug therapy Metabolism Metabolites Mushrooms Oral administration Pharmacokinetics Pharmacology Plasma Psilocybin - adverse effects Psilocybin - analogs & derivatives Psilocybin - pharmacology Psilocybin - therapeutic use Psychedelic drugs Review |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--H6urRPAkFrdNm4cXEXHxoih42NuSV2FBuuu2CvvvnWm7LSLuRSgU2qRNOzPJJDP5PkIuwKU3PFY-4C6GCUrCbaBSzQNuE-VsGIMTbEqyCfH8LAcD9VIvuOV1WuW8Tyw7aje2uEZ-jd2okhgmvJ18BMgahdHVmkJjmawibTbquRg0E66YCVkl2Cuweqg5j2oiZDRexGsR7lWRSLzSYiv8HKP-cDzLAai_9d-mb5PN2vWkd5Wu7JAln-2S9ac6uL5HXl_yEQxtM5grUzhKpMs2GfqGalrtc6HjlI6KnE5a1OvZFc116gs468xRj7gU2s72yVv_4e3-MagZFwILjlkRuJ60iRdc89iwUDvhUyG8sIaZCHd7OK_BYBXYuIrSSMvIJCFPXGhNiKgv7ICsZOPMHxHKmLI2CU2qezY2yqrUSS3ihMXSMK9Yh1w1v3tYm00-rFLOxPCXdDqkN5fI0Nbg5cih8b6oymVTZVIhdywq3J2Lrm1NK7cOOW9ug_lhTEVnfvwJZTh0gJKzCL7osFKP5m0ILReCu3q8-OEnZAM57Kuswi5ZKaaf_pSs2a9ilE_PSo3-BmB490c priority: 102 providerName: ProQuest |
| Title | Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy |
| URI | https://www.cambridge.org/core/product/identifier/S1092852922000888/type/journal_article https://www.ncbi.nlm.nih.gov/pubmed/35811423 https://www.proquest.com/docview/2847984529 https://www.proquest.com/docview/2688086323 |
| Volume | 28 |
| WOSCitedRecordID | wos000844412000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2165-6509 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0043783 issn: 1092-8529 databaseCode: 7X7 dateStart: 20120601 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2165-6509 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0043783 issn: 1092-8529 databaseCode: BENPR dateStart: 20120601 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 2165-6509 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0043783 issn: 1092-8529 databaseCode: M2M dateStart: 20120601 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swED_aZoy9rPteti5osKdRk1iy9bG3tbTbGAnZ1ge_GUmWITCcELuD_Pc7WbazD1rYw8DYIMuydZLuTr673wG8QZXe8ES5iBcJblBSbiNVah5xm6rCxgkqwaZNNiEWC5llankAWR8L490qB4yD1pLf5kfbBPjT6aoIPjRuO_0WzxSVKVXUR5v4jZz_aTnthiDvCH8II9RgKC7Z0afP2YdFz6UTJmRwvlfIEbCV3uLp4aT_bPlX3IXf5dcNSmkrnC6P_1-3HsD9TmEl70PJQzhw1SO4O-9M8o_hy7JeoUDc4Q6b4NHiY-5dqN8RTUJ0DFmXZNXUZLPHyt6dklqXrsGrrgriPJqFtrsncHV5cXX-MeryNEQW1bkmKmbSpk5wzRPDYl0IVwrhhDXMUB8jUjiNy1whZ1C0pFpSk8Y8LWJrYo8Vw57CUbWu3HMgjClr09iUemYTo6wqC6lFkrJEGuYUG8PpQMW8I0mdB0c1kf9FujHM-rHKbQd57jNvfL_tkbfDI5uA93Fb5ZN-Auy_xst7Jb09ewyvh9u4aL0lRldufY11OLJNyRnFHj0LE2d4mweki1HJffFvfX0J9yjqX8E38QSOmu21ewV37I9mVW8ncCgy0Z7lBEZnF4vl10m3IrB0Tuc_AfaLEic |
| linkProvider | Cambridge University Press |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3di9QwEB_OU9QXvz9WT42gL3LFbdImjSAi6nHH3S0n7MO-lXwVFqS7XnvK_lH-j870ExH37R6EQiFN0qSZTGY6M78BeIUivZWJDpH0CSooqXSRLoyMpEu1d3GCQrBtkk2o2SxbLPTZDvzqY2HIrbLniQ2j9itH_8jfEhvVGZkJP6y_R5Q1iqyrfQqNliyOw-YnqmzV-6PPuL6vOT_4Mv90GHVZBSKHwkcd-Wnm0qCkkYkVsfEqFEoF5aywnCIafDBIlKiKTzUvuMm4TWOZ-tjZmJBNBHZ7Ba4iG1ek66nFoN8lQmWtP79GJoMD7Y2ohFBNhVTGKTQmozwvI5TDn0fiP-Tc5rw7uP2ffak7cKsTrNnHdifchZ1Q3oPrp53rwH34elYt8eDe2GXJ8GpwPEdX73fMsDaKh60Ktqwrth4xvTf7rDJFqPFuSs8CoW4Yt3kA88uYz0PYLVdleAxMCO1cGtvCTF1itdOFz4xKUpFkVgQtJrA_rG7eMYUqbx3qVP4XMUxg2hNA7jpodsoQ8m1bkzdDk3WLS7Kt8l5PKeNoRjKZwMvhMTIXshiZMqwusI5E9p5JwXFGj1pqHN5GwHkxCuNPtnf-Am4czk9P8pOj2fFTuMlRRmz9J_dgtz6_CM_gmvtRL6vz581mYpBfMkn-BjjsUlQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3da9RAEB9qleKL9duzVVfQF2noZTfZ7BaKiPWw1B4n9KFvYb8CB5I7m1S5P83_zpl8XBDx3vogBAKb3c1u9rczs9nZ3wC8QZPeykSHSPoEFyipdJEujIykS7V3cYJGsG2CTWTTqbq81LMt-NWfhSG3yl4mNoLaLxz9Iz8kMaoVbRMeFp1bxOxk8n75PaIIUrTT2ofTaCFyFlY_cflWHZ-e4Fi_5Xzy6eLj56iLMBA5NETqyI-VS0MmjUysiI3PQpFlIXNWWE6nG3wwCFBclo81L7hR3KaxTH3sbEwsJwKrvQW3swTNDvIa5Oe9EkhEplrffo0CBxvdb6gSWzUlUhqnYzKKYr4MtA5_qsd_2LyN7pvs_sdf7T7c6wxu9qGdIQ9gK5QPYee8cyl4BF9n1RwV-srOS4ZXw-85uIAfMcPa0z1sUbB5XbHlwPW9OmCVKUKNd1N6FoiNw7jVY7i4if48ge1yUYZnwITQzqWxLczYJVY7XXhlEB4iUVYELUZwsB7pvBMWVd462mX5X8AYwbgHQ-46ynaKHPJtU5F36yLLlq9kU-b9HjVDawbIjOD1-jEKHdpJMmVYXGMeiWJfScGxR09bZK7fRoR6MRrpzzdX_gp2EIn5l9Pp2R7c5Wg6tm6V-7BdX12HF3DH_ajn1dXLZl4xyG8Ykb8B9UFbFw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psilocybin+in+neuropsychiatry%3A+a+review+of+its+pharmacology%2C+safety%2C+and+efficacy&rft.jtitle=CNS+spectrums&rft.au=Dodd%2C+Seetal&rft.au=Norman%2C+Trevor+R&rft.au=Eyre%2C+Harris+A&rft.au=Stahl%2C+Stephen+M&rft.date=2023-08-01&rft.issn=1092-8529&rft.volume=28&rft.issue=4&rft.spage=416&rft_id=info:doi/10.1017%2FS1092852922000888&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1092-8529&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1092-8529&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1092-8529&client=summon |